Exosomal circRNAs as promising liquid biopsy biomarkers for glioma

Liquid biopsy strategies enable the noninvasive detection of changes in the levels of circulating biomarkers in body fluid samples, providing an opportunity to diagnose, dynamically monitor, and treat a range of diseases, including cancers. Glioma is among the most common forms of intracranial malig...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1039084
Main Authors Wu, Xiaoke, Shi, Mengmeng, Lian, Yajun, Zhang, Haifeng
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 14.04.2023
Subjects
Biomarkers
Brain Neoplasms - diagnosis
Brain Neoplasms - genetics
exosomal circRNAs
exosome
glioma
Glioma - diagnosis
Glioma - genetics
Humans
Immunology
liquid biopsy
Liquid Biopsy - methods
RNA, Circular
glioma
exosome
biomarkers
liquid biopsy
exosomal circRNAs
Online AccessGet full text

Cover

More Information
Summary:Liquid biopsy strategies enable the noninvasive detection of changes in the levels of circulating biomarkers in body fluid samples, providing an opportunity to diagnose, dynamically monitor, and treat a range of diseases, including cancers. Glioma is among the most common forms of intracranial malignancy, and affected patients exhibit poor prognostic outcomes. As such, diagnosing and treating this disease in its early stages is critical for optimal patient outcomes. Exosomal circular RNAs (circRNAs) are involved in both the onset and progression of glioma. Both the roles of exosomes and methods for their detection have received much attention in recent years and the detection of exosomal circRNAs by liquid biopsy has significant potential for monitoring dynamic changes in glioma. The present review provides an overview of the circulating liquid biopsy biomarkers associated with this cancer type and the potential application of exosomal circRNAs as tools to guide the diagnosis, treatment, and prognostic evaluation of glioma patients during disease progression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Junhui Chen, Shenzhen Hospital, Peking University, China
Reviewed by: Ke Zen, Nanjing University, China; Takanobu Tagawa, National Cancer Institute (NIH), United States
These authors have contributed equally to this work
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1039084